TP53 and lung cancer: Paradoxically, tumor-intrinsic IFNγ signaling has also been shown to impede antitumor immunity (45), including in a CRISPR screen using an orthotopic KRASG12D p53−/− lung cancer model similar to the one used in this study (25).